Status:
COMPLETED
HDtDCS in Logopenic Variant PPA: Effects on Language and Neural Mechanisms
Lead Sponsor:
Medical College of Wisconsin
Conditions:
Primary Progressive Aphasia
Eligibility:
All Genders
45+ years
Phase:
NA
Brief Summary
This study aims to evaluate the effectiveness of a therapy called High-Definition Transcranial Direct Current Stimulation (HD-tDCS) for the treatment of the language deficits experienced by people wit...
Detailed Description
The logopenic variant of Primary Progressive Aphasia (lvPPA) is an untreatable neurodegenerative disorder that is often referred to as the 'language form' of Alzheimer's Disease (AD). Transcranial Dir...
Eligibility Criteria
Inclusion
- Diagnosed with language variant Primary Progressive Aphasia (lvPPA) subtype, defined as either clinical lvPPA or imaging-supported lvPPA in accordance with the most recent diagnostic criteria (Mesulam., 2001; Gorno-Tempini et al., 2011).
- Fluent in English.
- 45 years of age or older.
- Structural brain MRI performed within 3 years prior to enrollment.
Exclusion
- Severe cognitive, auditory or visual impairments that would preclude cognitive testing.
- Presence of major untreated or unstable psychiatric disease.
- A chronic medical condition that is not treated or is unstable.
- The presence of cardiac stimulators or pacemakers.
- Any metal implants in the skull
- Contraindications to MRI
- History of seizures
- History of dyslexia or other developmental learning disabilities.
Key Trial Info
Start Date :
February 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 18 2022
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT03805659
Start Date
February 24 2020
End Date
May 18 2022
Last Update
June 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226